Back to Tim Ferriss

How to Legalize Medical Psychedelics in Your Country — Tania de Jong on Australia’s Breakthrough

Tim FerrissSeptember 19, 20262h 0m
Topics76
The Moment Australia Rescheduled Psychedelics0:00The Origin Story: The Trip Treatment0:30First Psychedelic Experience in the Netherlands2:30The Mystical Experience and Integration4:32Second Journey and Recognition of Therapeutic Potential6:30Building Global Networks and Rick Doblin's Influence8:30Founding Mind Medicine Australia10:00The Rescheduling Campaign Strategy12:00Building a National Movement14:30Strategic Alliances and the David Nutt Roadshow17:30The Persistence Strategy19:30Connecting with Global Leaders20:30Time with Ram Dass27:18Ram Dass's Story About His Guru28:02Building Connections Through Ram Dass30:30Launching Mind Medicine Australia31:00The 2022 TGA Presentation32:01Vanessa's Story and Request for Psychedelic Therapy33:30The Rescheduling Victory35:00Authorized Prescriber Status and Clinic Rollout36:31The Risk of Inaction38:00Treatment Protocol and Integration39:00Split Between MDMA and Psilocybin Treatments40:03The Value of MDMA41:00Therapy Modalities and Integration43:30Projected Patient Numbers45:31Clinical Trial Costs and Real-World Evidence47:00Payer Engagement and Funding51:00Philanthropic Commitment53:00Syrian Rue as MAOI Inhibitor with Psilocybin53:59Personal Background and Control Issues55:30Dosing and Administration Protocol57:04Lemon Tek Biochemistry58:30Experience Comparison with and without Syrian Rue1:00:02Headache Considerations and Individual Variation1:02:00Group vs Individual Sessions1:04:00UCSF AIDS Survivor Study1:05:30Mind Medicine Australia Formation Challenges1:06:30Hiring Challenges with Lived Experience1:10:02Personal Attacks and Resilience Requirements1:12:32Remarkable Effect Sizes and Treatment Resistance1:13:30Critical Period and Integration Importance1:16:03TGA Engagement Strategy1:18:31Current Advocacy Efforts1:19:30Real-World Examples Driving Policy Change1:20:33Current Regulatory Status and Ongoing Dialogue1:21:02Maintaining Safety Standards While Reducing Bureaucratic Constraints1:22:30Group Therapy and Integration Protocols1:23:30Treatment Costs and Financial Accessibility1:24:01Clinic Development and Training Infrastructure1:25:02Alternative Compounds and Treatment Models1:27:00Ketamine's Role and Limitations1:31:30Natural vs Synthetic Compounds1:34:00Personal Ketamine Experience and Chronic Pain Benefits1:36:31Global Regulatory Developments1:40:31Advocacy Strategy and Persistence1:42:01Personal Growth Through the Process1:44:00Persistence and Timing in Advocacy1:46:13Patient Support Fund1:47:00Certificate in Psychedelic Assisted Therapies1:48:31Growing Markets and Resources1:49:30Webinar Series1:50:01Building a Global Movement1:50:30The Value of Curiosity1:51:02Inner Exploration1:51:33Psychedelics as Catalysts for Meditation1:52:32We're All Walking Each Other Home1:53:00Documentary Recommendation1:53:32Contact Information1:54:01Gratitude and Impact1:54:30Changing a Nation and the World1:55:32Newsletter Impact1:56:00The Power of Outsider Perspectives1:57:02The Importance of Asking1:58:00Final Call to Action1:58:31Closing Message1:59:01
In a Nutshell

Tania de Jong and her husband drove Australia to become the first country to reschedule psilocybin and MDMA from prohibited substances to controlled medicines in 2023 through Mind Medicine Australia, a charity they founded in 2019. Their campaign succeeded by submitting repeated evidence-based applications to the TGA, training over 750 clinicians, building 30+ local chapters, and leveraging high-profile presentations like David Nutt's to regulators and public testimony from patients like Vanessa whose husband died by suicide after treatment-resistant depression. The result is over 400 patients treated at 20+ clinics with 60-80% remission rates, establishing a model now influencing global policy while de Jong urges continued advocacy for expanded access.

AI-Generated Notes

These notes were generated by AI and may contain inaccuracies.

Tania de Jong recounts the pivotal moment when her husband informed her that psilocybin and MDMA had been rescheduled in Australia. Initially disbelieving, she examined the document herself, convinced there must be an error. Upon confirming the rescheduling, they celebrated with dancing in their kitchen, describing the moment as unbelievable and amazing. Headlines emerged worldwide declaring Australia as the first country to achieve this milestone, positioning the nation as a global leader in the field.

The conversation traces back to 2015 when de Jong first encountered Tim Ferriss's blog post announcing a $100,000 donation to Imperial College for psilocybin depression research. Initially, she had been reading his books and following his biohacking experiments. The blog post referenced the New Yorker article "The Trip Treatment" by Michael Pollan, which explored psilocybin research at Johns Hopkins with Roland Griffiths. De Jong, who had never consumed alcohol, coffee, or any drugs, was profoundly impacted by the article and convinced her skeptical husband to pursue participation in a clinical trial.

After being denied entry to European clinical trials due to lack of mental illness diagnosis, de Jong and her husband were connected to a guide in the Netherlands through the Psychedelic Society. They flew to Europe for their first psilocybin experience. De Jong describes being petrified beforehand, writing her last wishes to her accountant 24-48 hours before the session due to fears of losing control or going crazy. The guide, dressed in white robes reminiscent of Ram Dass, provided no clear answers to her husband's practical questions about the experience.

Sign in to read the full notes

Get access to AI-generated notes, topic timestamps, and more.